



Article Green and Efficient Construction of Chromeno[3,4-c]pyrrole Core via Barton–Zard Reaction from 3-Nitro-2*H*-chromenes and Ethyl Isocyanoacetate

Ivan A. Kochnev, Alexey Y. Barkov ^(D), Nikolay S. Zimnitskiy ^(D), Vladislav Y. Korotaev *^(D) and Vyacheslav Y. Sosnovskikh *^(D)

Institute of Natural Sciences and Mathematics, Ural Federal University, 620000 Ekaterinburg, Russia * Correspondence: korotaev.vladislav@urfu.ru (V.Y.K.); vy.sosnovskikh@urfu.ru (V.Y.S.)

Abstract: A regioselective one-pot method for the synthesis of 1-ethyl 2,4-dihydrochromene[3,4-c]pyrroles in 63–94% yields from available 2-phenyl-, 2-trifluoro(trichloro)methyl- or 2-phenyl-2-(trifluoromethyl)-3-nitro-2*H*-chromenes and ethyl isocyanoacetate through the Barton–Zard reaction in ethanol at reflux for 0.5 h, using K₂CO₃ as a base, has been developed.

Keywords: 3-nitro-2*H*-chromenes; ethyl isocyanoacetate; Barton–Zard reaction; 2,4-dihydrochromeno[3,4*c*]pyrroles

1. Introduction

The chromenopyrrole moiety is present in a wide range of natural and synthetic compounds with a number of important useful properties [1-15]. Thus, chromeno[3,4-b] pyrrole scaffold is the basis of the skeleton of type I lamellarin alkaloids isolated from marine mollusks, tunicates and sponges [1,2] (Figure 1). Some of them have shown anticancer activity [3,4], including against multidrug-resistant cancer cell lines [5], as well as anti-HIV-1 activity at noncytotoxic concentration [6]. Synthetic chromeno[3,4-b]pyrrole derivatives 1 exhibited antibacterial activity against Staphylococcus aureus and Escherichia coli comparable to that of gentamicin [7]. Significant pharmacological activity was also found in chromeno[4,3-b]- and chromeno[3,4-c]pyrrole derivatives. For example, 1,3-diaryl-substituted pyrrolo[3,2-c]coumarin **2** is a benzodiazepine receptor ligand [8], while pyrrolo[3,4-*c*]coumarin-1-carboxylic acid **3** has shown high antibacterial activity against Gram-positive and Gram-negative bacteria [9] (Figure 1). Pericyclic pyrrolo[3,4-c]coumarin 4 emits blue light and may be tested as bluelight emitters with an electron-transporting ability [10] (Figure 1). In view of the above, the development of methods for the synthesis of these classes of compounds is being carried out by various scientific groups, and the search for new effective approaches to the design of chromenopyrrole scaffolds continues [11–15].

There are several strategies for the synthesis of the chromeno[3,4-*c*]pyrrole core. The most important ones are shown in Scheme 1. Wang et al. developed an efficient method for the synthesis of pyrrolo[3,4-*c*]coumarins **5** via FeCl₃-promoted three-component reaction between 2-hydroxy- β -nitrostyrenes, dimethyl acetylenedicarboxylate and amines [16]. Fused pyrroles **6** were obtained by Khavasi et al. [17] and Alizadeh et al. [18] from 3-acylcoumarins or salicylaldehydes and β -keto esters through a two- or three-component reaction using the Van Leusen protocol. Samanta et al. reported the synthesis of 2-(2,4-dihydrochromeno[3,4-*c*]pyrrol-1-yl)acetates **8** from 3-(3-formyl-2*H*-chromen-4-yl)acrylates **7** by treatment with hydroxylamine hydrochloride, amino alcohols or sodium azide [19,20]. Recently, a metal-free method for the synthesis of chromeno[3,4-*c*]pyrroles **9** based on nitrative cyclization of the corresponding 1,7-diynes with *tert*-butyl nitrite in the presence of water has been developed [21].



Citation: Kochnev, I.A.; Barkov, A.Y.; Zimnitskiy, N.S.; Korotaev, V.Y.; Sosnovskikh, V.Y. Green and Efficient Construction of Chromeno[3,4-c]pyrrole Core via Barton–Zard Reaction from 3-Nitro-2*H*-chromenes and Ethyl Isocyanoacetate. *Molecules* **2022**, 27, 8456. https://doi.org/10.3390/ molecules27238456

Academic Editors: Theodora Venera Apostol, George Mihai Nitulescu and Laura Ileana Socea

Received: 11 November 2022 Accepted: 27 November 2022 Published: 2 December 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).



Figure 1. Representative natural and synthetic chromenopyrroles.

There are also reports on the synthesis of 1,3-diphenylpyrrole[3,4-*c*]coumarin by cycloaddition of the azomethine ylide generated from benzaldehyde and phenylglycine to 4-phenylsulfinylcoumarin [22], 2-benzyl-1-(pyridin-2-ylmethyl)-2,4-dihydrochromeno[3,4*c*]pyrrole from 4-bromo-2*H*-chromene-3-carbaldehyde, benzylamine and 2-ethynylpyridine via the palladium-catalyzed one-pot Sonogashira reaction [23], and 2-benzyl-3-methyl-1-phenyl-2,4-dihydrochromeno[3,4-*c*]pyrrole from the corresponding 1,7-diyne through intramolecular [3+2] cycloaddition [24]. However, these methods are represented by single examples. Pyrrolocoumarin 4 was synthesized from 4-hydroxycoumarin, triethyl orthoformate and glycine in two steps in an overall yield of 81% [6]. A similar approach has been used to obtain 4,4-dialkyl-2-acetyl-2,4-dihydrochromeno[3,4-*c*]pyrroles from 2,2-dialkyl-4oxochromane-3-carbaldehydes [25]. More recently, a copper-catalyzed [1,2]-Stevens-type asymmetric cascade cyclization/rearrangement of OTBS-substituted *N*-propargyl ynamides to form chromeno[3,4-*c*]pyrroles bearing a chiral C-4 stereocenter has been reported [26].

The Barton–Zard reaction is an efficient one-pot method for the synthesis of 5-unsubstituted pyrroles from readily available conjugated nitroalkenes and alkyl isocyanoacetates [27–31]. From this point of view, 3-nitro-2*H*-chromenes are suitable substrates for the design of a chromeno[3,4-*c*]pyrrole scaffold. Indeed, due to the presence of a β -nitrostyrene fragment in the molecule, 3-nitro-2*H*-chromenes are widely used in the synthesis of fused polyhete-rocyclic systems [32–34]. The introduction of a trifluoromethyl group into a drug molecule often leads to an increase in its physiological activity because of improvements to the transport characteristics of the drug and an increase in its metabolic stability [35,36]. We have recently developed methods for the synthesis of trifluoromethyl-substituted chromenopy-rroli(zi)dines with pronounced cytotoxic activity against HeLa and RD cancer cells [37–39]. In this work, we report an eco-friendly and efficient approach to the synthesis of 2,4-dihydrochromeno[3,4-*c*]pyrroles **12** from 2-mono- and 2,2-disubsituted 3-nitrochromenes **10** and ethyl isocyanoacetate **11** via the Barton–Zard reaction (Scheme 1).



 $R^1 = CF_3$, CCI_3 , Ph, $R^2 = H$; $R^1 = CF_3$, $R^2 = Ph$; R^3 , $R^4 = H$, Br, CI, MeO, EtO

Scheme 1. Strategies for the synthesis of the chromeno[3,4-c]pyrroles framework.

2. Results and Discussion

In order to obtain chromeno[3,4-*c*]pyrroles **12**, we optimized conditions for the reaction of 2-trifluoromethyl-substituted chromene **10aa** with ethyl isocyanoacetate **11** to form chromeno[3,4-*c*]pyrrole **12aa** (Scheme 2, Table 1).



Scheme 2. Reaction of 3-nitro-2H-chromenes 10aa with ethyl isocyanoacetate 11.

 Table 1. Condition optimization for the reaction of 10aa with 11^a.

Entry	Base	Equiv.	Solvent	Yield ^b , %	
				Method A	Method B
1	DBU	1.1	THF	86	71
2	DABCO	1.1	THF	58	44
3	K ₂ CO ₃	1.1	THF	61	67
4	DBU	1.1	MeCN	57	85
5	DABCO	1.1	MeCN	65	72
6	K ₂ CO ₃	1.1	MeCN	44	60
7	DBU	1.1	EtOH	72	85
8	DABCO	1.1	EtOH	89	83
9	K ₂ CO ₃	1.1	EtOH	85	86
10	K_2CO_3	1.5	EtOH	89	94
11	K_2CO_3	2.0	EtOH	95	94
12	K ₂ CO ₃	3.0	EtOH	93	95

^a A solution of **11** (29 mg, 0.26 mmol, 1.3 equiv.) in 1 mL of a solvent was added to a mixture of **10aa** (49 mg, 0.20 mmol, 1.0 equiv.) and the corresponding base in 2 mL of a solvent, and the reaction mixture was stirred at room temperature for 1 h (method A) or under reflux for 0.5 h (method B). ^b Isolated yield.

The reaction was carried out at room temperature (method A) or at reflux (method B). Three bases (DBU, DABCO and K_2CO_3) and three solvents (THF, MeCN and EtOH) were tested. It was found that regardless of the base used, the starting chromene **10aa** was absent in the reaction mixture after 1 h or 0.5 h under the conditions of method A or B, respectively (monitoring by TLC). In ethanol, all three bases were effective both at room temperature and at boiling (entries 7–9). In MeCN, the yields of the product increased noticeably with a rise in the temperature (entries 4–6). In contrast, if THF was used as the solvent, the yields decreased at reflux when DBU or DABCO were used as bases (entries 1–2). The best yield of **12aa** (94%) was achieved when the reaction was carried out in ethanol at reflux using 1.5 equiv. K_2CO_3 (entry 10). A further increase in the amount of base did not significantly affect the yield of product (entries 11–12).

Next, under optimized conditions, the substrate scope for the synthesis of chromeno[3,4c]pyrroles 12 were examined by varying the substituents R^1 - R^4 in nitrochromenes 10 (Scheme 3).

The substituents at the 2-position of chromene **10** had a notable effect on the yields of the products **12** (Scheme 3). The highest yields (83–94%) were observed in the reactions of isonitrile **11** with 2-trifluoromethyl- and 2-phenyl-substituted chromenes **10aa–ag** and **10ba–bg**. The yields of 2-trichloromethyl-substituted pyrroles **12ca–cg** decreased by 7–14% compared to 2-trifluoromethyl-substituted analogs **12aa–ag**. Lower yields in the reactions involving chromenes **12ca–cg** were probably associated with the formation of 2-(dichloromethylidene)chromenes as a result of the elimination of HCl under the action of the base. We have already observed a similar process earlier in the reactions of these chromenes **10aa–ag** or **10ba–bg** (Ph or CF₃ group, respectively) reduced the yields of products **12da–dg** to 63–76% due to additional steric hindrances for attacking the double bond by the reagent. At the same time, the yields of pyrroles **12** were almost independent from the donor–acceptor properties of substituents R³ and R⁴. Replacement of the hydrogen atoms at the positions 6 and 8 of the starting chromenes **10** with the donor MeO or EtO groups only slightly reduced the yields of compounds **12**.



Scheme 3. Synthesis of 2,4-dihydrochromeno[3,4-c]pyrroles 12.

To test the scalability of the procedure for the synthesis of 4-substituted 2,4dihydrochromeno[3,4-*c*]pyrroles **12**, the gram-scale reaction of chromene **10aa** (1.00 g) with isonitrile **11** (0.60 g) was carried out under the standard condition to obtain the target product **12aa** (1.20 g) in 94% yield (Scheme 4).



Scheme 4. Gram-scale synthesis of 2,4-dihydrochromeno[3,4-c]pyrrole 12aa.

The probable reaction mechanism includes the Michael addition of isonitrile **11** to chromene **10**, intramolecular cyclization of the nitronate anion **A** into pyrroline **B**, protonation of anion **B**, elimination of nitrous acid in pyrroline **C**, and 1,3-H shift in 3*H*-pyrrole **D** to form chromeno[3,4-*c*]pyrrole **12** (Scheme 5) [27].



Scheme 5. Probable mechanism for the reaction leading to chromeno[3,4-c]pyrroles 12.

The ¹H NMR spectra of chromeno[3,4-c]pyrroles **12** contained a slightly broadened singlet of the 2-NH proton in the range of 9.08–9.53 ppm. The H-3 proton manifested as a doublet, or as a doublet of doublets at 6.36–7.16 ppm, with a coupling constants ${}^{3}J_{H3,H2} = 2.6–3.1$ Hz and ${}^{4}J_{H3,H4} = 0.7$ Hz in the spectra of 2-monosubstituted chromenopyrroles **12aa–cg**, and as a doublet of quartets at 7.16–7.23 ppm with coupling constants ${}^{3}J_{H3,H2} = 2.6–2.8$ Hz, ${}^{5}J_{H,F} = 1.4–1.5$ Hz in the spectra of 2,2-disubstituted chromenopyrroles **12da–dg**. The signal of the H-9 proton was unshielded with respect to the other protons of the benzene ring and resonated at 8.10–8.89 ppm. The ¹⁹F NMR spectra of products **12aa–ag** featured a doublet of the trifluoromethyl group at 82.6–83.0 ppm with ${}^{3}J_{F,H} = 6.6–6.8$ Hz, while in the spectra of compounds **12da–dg** this group manifested as a singlet in the range of 84.3–85.2 ppm. The ¹³C NMR spectra of these compounds contained quartets of the CF₃ group and the C-4 atom in the range of 122.9–124.1 and 71.0–82.2 ppm with coupling constants 283.1–284.3 and 30.8–34.8 Hz, respectively.

To assess the possibility of using pyrroles **12** in organic synthesis, some transformations of the pyrrole ring were carried out (Scheme 6). It was found that chromenopyrrole **12aa** was methylated at the nitrogen atom to form the *N*-methyl derivative **13** in 76% yield.

Treatment of compound **12aa** with phenylboronic acid by the Chan–Evans–Lahm coupling reaction led to the corresponding *N*-phenylpyrrole **14** in 45% yield. 3-Bromo derivative **15** was obtained in 55% yield by bromination of compound **15** with *N*-bromosuccinimide.



Scheme 6. Some transformations of the pyrrole ring of compound 12aa.

In summary, a green and efficient regioselective method for the synthesis of 4-substituted 2,4-dihydrochromeno[3,4-*c*]pyrroles has been developed by the Barton–Zard reaction, using K_2CO_3 as a base and ethanol as a solvent. The availability of the starting 3-nitro-2*H*-chromenes, operational simplicity and scalability, as well as the possibility of further functionalization of the products, open up prospects for the synthesis of libraries of compounds bearing a chromeno[3,4-*c*]pyrrole framework, which are of undoubted interest for medicinal chemistry, especially due to the presence of the CF₃ group.

3. Materials and Methods

3.1. General

IR spectra were recorded on a Shimadzu IRSpirit-T spectrometer using an attenuated total reflectance (ATR) unit (FTIR mode, ZnSe crystal); the absorbance maxima (ν) are reported in cm⁻¹. NMR spectra (See Supplementary Materials) were recorded on Bruker Avance III-500 (¹H, 500 MHz; ¹⁹F, 471 MHz; ¹³C, 126 MHz) and Bruker DRX-400 (¹H, 400 MHz; ¹⁹F, 376 MHz) spectrometers in CDCl₃. The chemical shifts (δ) are reported in ppm relative to the internal standard TMS (¹H NMR), C₆F₆ (¹⁹F NMR), and residual signal of the solvent (¹³C NMR). The HRMS spectra were obtained using the UHR-QqTOF maXis Impact HD (Bruker Daltonics, Billerica, MA, USA) mass spectrometer. Melting points were determined on an SMP40 apparatus. Monitoring of the reaction progress and assessment of the purity of synthesized compounds were carried out by TLC on Sorbfil PTSKh-AF-A-UF plates (eluent EtOAc–hexane, 1:3). All solvents used were dried and distilled by standard procedures. The starting chromenes **10** were prepared according to described procedures [41–43]. Compounds **13–15** were obtained according to the procedures analogous to those described in [44–46].

3.2. Synthesis of Compounds 12aa-dg

General procedure. To a mixture of the appropriate 3-nitro-2*H*-chromene **10** (0.5 mmol) and K_2CO_3 (104 mg, 0.75 mmol) in EtOH (4 mL), a solution of ethyl isocyanoacetate **11** (74 mg, 0.65 mmol) in EtOH (2 mL) was added dropwise with stirring. Then, the mixture was refluxed for 0.5 h with stirring (TLC control, EtOAc–hexane (1:3)). After completion of the reaction, 1 mL of 5% hydrochloric acid was added and the reaction mixture was evaporated under reduced pressure. Then, water (25 mL) was added to the residue, the

precipitate was filtered, dried at 75 °C and recrystallized from a dichloromethane–hexane (2:1) system to give products **12** as beige powders.

Ethyl 4-(*trifluoromethyl*)-2,4-*dihydrochromeno*[3,4-*c*]*pyrrole*-1-*carboxylate* (**12a**). Yield 146 mg (94%), mp 109–110 °C. IR (ATR) v 3286 (NH), 1667 (C=O). ¹H NMR (500 MHz, CDCl₃) δ 1.43 (t, 3H, *J* = 7.1 Hz), 4.42 (q, 2H, *J* = 7.1 Hz), 5.57 (q, 1H, *J* = 6.6 Hz), 6.92 (d, 1H, *J* = 3.0 Hz), 7.04 (dd, 1H, *J* = 8.0, 1.4 Hz), 7.06 (td, 1H, *J* = 8.0, 1.4 Hz), 7.22 (td, 1H, *J* = 8.0, 1.5 Hz), 8.68 (dd, 1H, *J* = 8.0, 1.5 Hz), 9.29 (s, 1H); ¹⁹F NMR (471 MHz, CDCl₃) δ 82.9 (d, *J* = 6.6 Hz, CF₃); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.0, 71.0 (q, ²*J*_{CF} = 34.2 Hz), 112.2, 116.9, 117.5, 117.8 (2C), 121.0, 122.5, 123.4 (q, ¹*J*_{CF} = 283.8 Hz), 127.6, 129.2, 151.7, 160.1. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₁₅H₁₃F₃NO₃ 312.0843, found 312.0846.

Ethyl 8-methoxy-4-(*trifluoromethyl*)-2,4-*dihydrochromeno*[3,4-*c*]*pyrrole*-1-*carboxylate* (**12ab**). Yield 145 mg (85%), mp 120–123 °C. IR (ATR) v 3275 (NH), 1676 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.42 (t, 3H, *J* = 7.1 Hz), 4.42 (q, 2H, *J* = 7.1 Hz), 5.52 (qd, 1H, *J* = 6.7, 0.4 Hz), 6.78 (dd, 1H, *J* = 8.8, 3.1 Hz), 6.91 (d, 1H, *J* = 3.1 Hz), 6.96 (d, 1H, *J* = 8.8 Hz), 8.37 (d, 1H, *J* = 3.1 Hz), 9.29 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 83.0 (d, *J* = 6.7 Hz, CF₃); ¹³C NMR (126 MHz, CDCl₃) δ 14.5, 55.7, 61.0, 70.9 (q, ²*J*_{CF} = 33.9 Hz), 112.1, 112.5, 115.4, 117.4, 117.5, 117.7, 118.3, 121.4, 123.4 (d, ¹*J*_{CF} = 283.6 Hz), 145.7, 154.8, 160.0. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₁₆H₁₅F₃NO₄ 342.0948, found 342.0953.

Ethyl 6-ethoxy-4-(trifluoromethyl)-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12ac**). Yield 147 mg (83%), mp 115–117 °C. IR (ATR) ν 3393, 1698, 1567, 1470, 1455, 1414, 1351, 1311. ¹H NMR (400 MHz, CDCl₃) δ 1.42 (t, 3H, *J* = 7.1 Hz), 1.44 (t, 3H, *J* = 7.0 Hz), 4.13 (q, 2H, *J* = 7.0 Hz), 4.41 (q, 2H, *J* = 7.1 Hz), 5.66 (q, 1H, *J* = 6.8 Hz), 6.90 (dd, 1H, *J* = 8.0, 1.4 Hz), 6.93 (d, 1H, *J* = 3.1 Hz), 6.98 (t, 1H, *J* = 8.0 Hz), 8.30 (dd, 1H, *J* = 8.0, 1.5 Hz), 9.33 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 82.9 (d, *J* = 6.8 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 14.9, 61.0, 65.4, 70.9 (q, ²*J*_{CF} = 34.3 Hz), 112.3, 115.0, 117.6, 117.9, 118.8, 120.1, 121.0, 121.9, 123.4 (q, ¹*J*_{CF} = 284.3 Hz), 141.8, 147.8, 160.1. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₁₇H₁₇F₃NO₄ 356.1105, found 356.1111.

Ethyl 8-chloro-4-(trifluoromethyl)-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12ad**). Yield 154 mg (89%), mp 169–170 °C. IR (ATR) v 3279 (NH), 1667 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.47 (t, 3H, *J* = 7.1 Hz), 4.44 (q, 2H, *J* = 7.1 Hz), 5.57 (q, 1H, *J* = 6.6 Hz), 6.94 (d, 1H, *J* = 3.1 Hz), 6.97 (d, 1H, *J* = 8.7 Hz), 7.16 (dd, 1H, *J* = 8.7, 2.6 Hz), 8.70 (d, 1H, *J* = 2.6 Hz), 9.47 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 82.8 (d, *J* = 6.6 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 14.3, 61.4, 71.0 (q, ²*J*_{CF} = 34.5 Hz), 112.0, 117.9, 118.1 (2C), 119.1, 119.5, 123.2 (q, ¹*J*_{CF} = 283.9 Hz), 127.3, 127.4, 128.8, 150.2, 160.2. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₅H₁₂ClF₃NO₃ 346.0454, found 346.0455.

Ethyl 8-bromo-4-(trifluoromethyl)-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12ae**). Yield 176 mg (90%), mp 177–178 °C. IR (ATR) \vee 3281 (NH), 1666 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.49 (t, 3H, *J* = 7.1 Hz), 4.45 (q, 2H, *J* = 7.1 Hz), 5.57 (q, 1H, *J* = 6.6 Hz), 6.92 (d, 1H, *J* = 8.7 Hz), 6.94 (d, 1H, *J* = 3.1 Hz), 7.30 (dd, 1H, *J* = 8.6, 2.4 Hz), 8.84 (d, 1H, *J* = 2.5 Hz), 9.39 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 82.8 (d, *J* = 6.6 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.5, 71.0 (q, ²*J*_{CF} = 34.0 Hz), 112.0, 114.9, 117.9, 118.1, 118.6, 119.3, 119.6, 123.2 (q, ¹*J*_{CF} = 283.7 Hz), 130.2, 131.7, 150.7, 160.2. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₅H₁₂BrF₃NO₃ 389.9947, found 389.9948.

Ethyl 6,8-*dichloro*-4-(*trifluoromethyl*)-2,4-*dihydrochromeno*[3,4-*c*]*pyrrole*-1-*carboxylate* (**12af**). Yield 167 mg (88%), mp 187–190 °C. IR (ATR): v 3278 (NH), 1671 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.47 (t, 3H, *J* = 7.1 Hz), 4.43 (dq, 1H, *J* = 10.3, 7.1 Hz), 4.47 (dq, 1H, *J* = 10.3, 7.1 Hz), 5.68 (q, 1H, *J* = 6.6 Hz), 6.97 (d, 1H, *J* = 3.1 Hz), 7.29 (d, 1H, *J* = 2.5 Hz), 8.68 (d, 1H, *J* = 2.5 Hz), 9.44 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 82.6 (d, *J* = 6.6 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.5, 71.4 (q, ²*J*_{CF} = 34.8 Hz), 111.9, 118.1, 118.3, 119.0, 120.3, 122.8, 122.9 (q, ¹*J*_{CF} = 283.6 Hz), 125.9, 127.3, 129.1, 146.1, 159.9. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₁₅H₁₁Cl₂F₃NO₃ 380.0063, found 380.0059.

Ethyl 6,8-dibromo-4-(trifluoromethyl)-2,4-dihydrochromeno[3,4-*c*]*pyrrole-1-carboxylate* (**12ag**). Yield 213 mg (91%), mp 187–188 °C. IR (ATR): ν 3278 (NH), 1668 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.47 (t, 3H, *J* = 7.1 Hz), 4.42 (dq, 1H, *J* = 11.0, 7.1 Hz), 4.46 (dq, 1H, *J* = 11.0, 7.1 Hz),

5.68 (q, 1H, J = 6.5 Hz), 6.97 (d, 1H, J = 3.1 Hz), 7.58 (d, 1H, J = 2.3 Hz), 8.84 (d, 1H, J = 2.3 Hz), 9.46 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 82.6 (d, J = 6.6 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.6, 71.4 (q, ² $J_{CF} = 34.7$ Hz), 111.8, 112.0, 114.8, 118.1, 118.3, 118.8, 120.8, 122.9 (d, ¹ $J_{CF} = 284.1$ Hz), 129.4, 134.6, 147.5, 159.9. HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₅H₁₁Br₂F₃NO₃ 467.9051, found 467.9051.

Ethyl 4-*phenyl*-2,4-*dihydrochromeno*[3,4-*c*]*pyrrole*-1-*carboxylate* (**12ba**). Yield 136 mg (85%), mp 91–93 °C. IR (ATR) v 3298 (NH), 1660 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.40 (t, 3H, *J* = 7.1 Hz,), 4.38 (dq, 1H, *J* = 10.9, 7.1 Hz), 4.44 (dq, 1H, *J* = 10.9, 7.1 Hz), 6.05 (s, 1H), 6.36 (d, 1H, *J* = 2.9 Hz), 7.01 (dd, 1H, *J* = 8.0, 1.1 Hz), 7.04 (td, 1H, *J* = 8.0, 1.1 Hz), 7.18 (td, 1H, *J* = 8.0, 1.5 Hz), 7.33–7.41 (m, 3H), 7.44–7.49 (m, 2H), 8.59 (dd, 1H, *J* = 8.0, 1.5 Hz), 9.18 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.5, 60.7, 76.0, 117.1, 117.6, 119.8, 121.5, 121.8, 123.4, 125.6, 127.6 (2C), 127.6, 128.5 (2C), 128.5, 128.8, 139.9, 153.9, 160.7. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₂₀H₁₈NO₃ 320.1281, found 320.1286.

Ethyl 8-methoxy-4-phenyl-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12bb**). Yield 145 mg (83%), mp 140–142 °C. IR (ATR) v 3281 (NH), 1673 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.42 (t, 3H, *J* = 7.1 Hz), 3.86 (s, 3H), 4.40 (dq, 1H, *J* = 10.8, 7.1 Hz), 4.43 (dq, 1H, *J* = 10.8, 7.1 Hz), 6.01 (s, 1H), 6.38 (dd, 1H, *J* = 2.9, 0.7 Hz), 6.77 (dd, 1H, *J* = 8.8, 3.1 Hz), 6.94 (d, 1H, *J* = 8.8 Hz), 7.34–7.42 (m, 3H), 7.45–7.50 (m, 2H), 8.28 (d, 1H, *J* = 3.1 Hz), 9.08 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.6, 55.8, 60.7, 75.9, 112.1, 115.0, 117.0, 117.1, 118.0, 120.3, 121.9, 123.6, 127.6, 128.4 (2C), 128.5 (2C), 139.9, 147.9, 154.4, 160.5. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₁H₂₀NO₄ 350.1387, found 350.1392.

Ethyl 6-ethoxy-4-phenyl-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12bc**). Yield 156 mg (86%), mp 85–87 °C. IR (ATR) v 3323 (NH), 1701 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.37 (t, 3H, *J* = 7.0 Hz), 1.40 (t, 3H, *J* = 7.1 Hz), 4.06 (dq, 1H, *J* = 9.8, 7.0 Hz), 4.09 (dq, 1H, *J* = 9.8, 7.0 Hz), 4.37 (dq, 1H, *J* = 11.0, 7.1 Hz), 4.40 (dq, 1H, *J* = 11.0, 7.1 Hz), 6.16 (s, 1H), 6.49 (dd, 1H, *J* = 2.8 Hz), 6.85 (dd, 1H, *J* = 8.0, 1.5 Hz), 6.95 (t, 1H, *J* = 8.0 Hz), 7.28–7.36 (m, 3H), 7.43–7.48 (m, 2H), 8.20 (dd, 1H, *J* = 8.0, 1.5 Hz), 9.19 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 14.9, 60.7, 65.1, 75.4, 114.5, 117.0, 117.2, 120.2, 120.9, 121.1, 121.4, 123.0, 127.3 (2C), 128.1, 128.3 (2C), 140.0, 143.7, 148.3, 160.6. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₂₂H₂₂NO₄ 364.1543, found 364.1550.

Ethyl 8-chloro-4-phenyl-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12bd**). Yield 154 mg (87%), mp 145–146 °C. IR (ATR) v 3303 (NH), 1668 (C=O). ¹H NMR (500 MHz, CDCl₃) δ 1.47 (t, 3H, *J* = 7.1 Hz), 4.41 (dq, 1H, *J* = 10.9, 7.1 Hz), 4.44 (dq, 1H, *J* = 10.9, 7.1 Hz), 6.06 (s, 1H), 6.42 (d, 1H, *J* = 2.6 Hz), 6.93 (d, 1H, *J* = 8.6 Hz), 7.12 (dd, 1H, *J* = 8.6, 2.6 Hz), 7.35–7.41 (m, 3H), 7.43–7.46 (m, 2H), 8.60 (d, 1H, *J* = 2.6 Hz), 9.20 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.2, 76.1, 117.3, 117.5, 118.8, 120.1, 121.1, 123.1, 126.7, 127.3, 127.6 (2C), 128.4, 128.6 (2C), 128.7, 139.5, 152.4, 160.7. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₀H₁₇CINO₃ 354.0891 found 354.0895.

Ethyl 8-bromo-4-phenyl-2,4-dihydrochromeno[3,4-*c*]*pyrrole-1-carboxylate* (**12be**). Yield 177 mg (89%), mp 141–143 °C. IR (ATR) v 3298 (NH), 1665 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.48 (t, 3H, *J* = 7.1 Hz), 4.41 (dq, 1H, *J* = 10.8, 7.1 Hz), 4.47 (dq, 1H, *J* = 10.8, 7.1 Hz), 6.06 (s, 1H), 6.42 (d, 1H, *J* = 2.9 Hz), 6.88 (d, 1H, *J* = 8.6 Hz), 7.31–7.42 (m, 3H), 7.42–7.48 (m, 2H), 8.73 (d, 1H, *J* = 2.5 Hz), 9.21 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.2, 76.1, 114.2, 117.3, 117.5, 119.3, 119.8, 121.7, 123.0, 127.6 (2C), 128.6 (2C), 128.7, 130.1, 131.3, 139.5, 152.9, 160.7. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₂₀H₁₇BrNO₃ 398.0386, found 398.0394.

Ethyl 6,8-dichloro-4-phenyl-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12bf**). Yield 163 mg (84%), mp 138–140 °C. IR (ATR) v 3317 (NH), 1662 (C=O). ¹H NMR (500 MHz, CDCl₃) δ 1.46 (t, 3H, *J* = 7.1 Hz), 4.41 (dq, 1H, *J* = 10.8, 7.1 Hz), 4.44 (dq, 1H, *J* = 10.8, 7.1 Hz), 6.22 (s, 1H), 6.57 (d, 1H, *J* = 2.9 Hz), 7.24 (d, 1H, *J* = 2.5 Hz), 7.34–7.39 (m, 3H), 7.41–7.45 (m, 2H), 8.53 (d, 1H, *J* = 2.5 Hz), 9.30 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.3, 76.1, 117.3, 117.8, 119.4, 122.3, 122.5, 123.4, 125.8, 126.3, 127.3 (2C), 128.5 (2C), 128.6, 128.6, 139.0, 148.1, 160.5. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₂₀H₁₆Cl₂NO₃ 388.0502, found 388.0505.

Ethyl 6,8-dibromo-4-phenyl-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12bg**). Yield 205 mg (86%), mp 185–187 °C. IR (ATR) \vee 3265 (NH), 1667 (C=O). ¹H NMR (400 MHz,

CDCl₃) δ 1.47 (t, 3H, *J* = 7.1 Hz), 4.42 (dq, 1H, *J* = 10.8, 7.1 Hz), 4.44 (dq, 1H, *J* = 10.8, 7.1 Hz), 6.24 (s, 1H), 6.58 (d, 1H, *J* = 2.9 Hz), 7.30–7.40 (m, 3H), 7.40–7.46 (m, 2H), 7.53 (d, 1H, *J* = 2.5 Hz), 8.70 (d, 1H, *J* = 2.5 Hz), 9.26 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.3, 76.0, 112.6, 113.9, 117.2, 117.9, 119.2, 122.4, 122.7, 127.2 (2C), 128.5 (2C), 128.6, 129.3, 134.0, 139.0, 149.5, 160.4. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₂₀H₁₆Br₂NO₃ 475.9491, found 475.9496.

Ethyl 4-(trichloromethyl)-2,4-dihydrochromeno[3,4-*c*]*pyrrole-1-carboxylate* (**12ca**). Yield 144 mg (80%), mp 135–137 °C. IR (ATR) v 3278 (NH), 1644 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.43 (t, 3H, *J* = 7.1 Hz), 4.43 (q, 2H, *J* = 7.1 Hz), 5.76 (s, 1H), 7.04 (dd, 1H, *J* = 8.0, 1.3 Hz), 7.06 (td, 1H, *J* = 8.0, 1.3 Hz), 7.12 (d, 1H, *J* = 3.1 Hz), 7.23 (td, 1H, *J* = 8.0, 1.6 Hz), 8.72 (dd, 1H, *J* = 8.0, 1.6 Hz), 9.37 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.5, 61.0, 81.9, 101.5, 113.8, 116.8, 116.9, 117.9, 120.4, 121.7, 122.1, 127.4, 129.3, 152.0, 160.2. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₁₅H₁₃Cl₃NO₃ 359.9956, found 359.9960.

Ethyl 8-methoxy-4-(*trichloromethyl*)-2,4-*dihydrochromeno*[3,4-*c*]*pyrrole*-1-*carboxylate* (**12cb**). Yield 152 mg (78%), mp 155–157 °C. IR (ATR) ν 3301 (NH), 1683 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.43 (t, 3H, *J* = 7.1 Hz), 3.85 (s, 3H), 4.43 (q, 2H, *J* = 7.1 Hz), 5.70 (s, 1H), 6.79 (dd, 1H, *J* = 8.8, 3.1 Hz), 6.99 (d, 1H, *J* = 8.8 Hz), 7.11 (d, 1H, *J* = 3.1 Hz), 8.41 (d, 1H, *J* = 3.1 Hz), 9.37 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.5, 55.7, 60.9, 81.9, 101.5, 111.8, 114.0, 115.5, 116.9, 117.3, 118.3, 120.4, 122.1, 146.0, 154.5, 160.1. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₁₆H₁₅Cl₃NO₄ 390.0062, found 390.0067.

Ethyl 6-ethoxy-4-(trichloromethyl)-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12cc**). Yield 152 mg (75%), mp 135–137 °C. IR (ATR) ν 3305 (NH), 1682 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.42 (t, 3H, *J* = 7.1 Hz), 1.46 (t, 3H, *J* = 7.0 Hz), 4.11 (dq, 1H, *J* = 9.7, 7.1 Hz), 4.18 (dq, 1H, *J* = 9.7, 7.1 Hz), 4.42 (q, 2H, *J* = 7.1 Hz), 5.86 (s, 1H), 6.90 (dd, 1H, *J* = 8.0, 1.6 Hz), 6.97 (t, 1H, *J* = 8.0 Hz), 7.13 (d, 1H, *J* = 3.1 Hz), 8.34 (dd, 1H, *J* = 8.0, 1.6 Hz), 9.38 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 15.0, 60.9, 65.4, 81.9, 101.4, 113.8, 114.8, 117.0, 118.9, 119.7, 120.4, 121.5, 121.7, 142.1, 147.7, 160.2. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₁₇H₁₇Cl₃NO₄ 404.021, found 404.0219.

Ethyl 8-chloro-4-(trichloromethyl)-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12cd**) Yield 156 mg (79%), mp 195–197 °C. IR (ATR) v 3278 (NH), 1664 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.48 (t, 3H, *J* = 7.1 Hz), 4.40 (dq, 1H, *J* = 10.8, 7.1 Hz), 4.47 (dq, 1H, *J* = 10.8, 7.1 Hz), 5.75 (s, 1H), 7.00 (d, 1H, *J* = 8.6 Hz), 7.14 (d, 1H, *J* = 3.0 Hz), 7.17 (dd, 1H, *J* = 8.6, 2.6 Hz), 8.75 (d, 1H, *J* = 2.6 Hz), 9.44 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.4, 82.0, 101.3, 113.7, 117.3, 118.0, 119.2, 120.3, 120.5, 127.1, 127.1, 128.9, 150.5, 160.2. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₁₅H₁₂Cl₄NO₃ 393.9566, found 393.9569.

Ethyl 8-bromo-4-(trichloromethyl)-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12ce**). Yield 176 mg (80%), mp 180–181 °C. IR (ATR) v 3277 (NH), 1664 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.49 (t, 3H, *J* = 7.1 Hz), 4.44 (dq, 1H, *J* = 10.8, 7.1 Hz), 4.47 (dq, 1H, *J* = 10.8, 7.1 Hz), 5.75 (s, 1H), 6.95 (d, 1H, *J* = 8.6 Hz), 7.14 (d, 1H, *J* = 3.1 Hz), 7.31 (dd, 1H, *J* = 8.6, 2.4 Hz), 8.87 (d, 1H, *J* = 2.4 Hz), 9.47 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.5, 81.9, 101.3, 113.6, 114.5, 117.3, 118.5, 119.8, 120.0, 120.6, 129.9, 131.8, 151.0, 160.3. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₁₅H₁₂BrCl₃NO₃ 437.9061, found 437.9067.

Ethyl 6,8-*dichloro*-4-(*trichloromethyl*)-2,4-*dihydrochromeno*[3,4-*c*]*pyrrole*-1-*carboxylate* (**12cf**). Yield 174 mg (81%), mp 143–144 °C. IR (ATR) ν 3282 (NH), 1668 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.47 (t, 3H, *J* = 7.1 Hz), 4.43 (dq, 1H, *J* = 10.8, 7.1 Hz), 4.46 (dq, 1H, *J* = 10.8, 7.1 Hz), 5.86 (s, 1H), 7.16 (d, 1H, *J* = 3.0 Hz), 7.29 (d, 1H, *J* = 2.5 Hz), 8.71 (d, 1H, *J* = 2.5 Hz), 9.53 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.5, 82.3, 100.8, 113.7, 117.6, 119.7, 120.5, 120.6, 122.7, 125.6, 126.9, 129.1, 146.5, 160.0. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₁₅H₁₁Cl₅NO₃ 427.9176, found 427.9174.

Ethyl 6,8-dibromo-4-(trichloromethyl)-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12cg**). Yield 207 mg (80%), mp 175–178 °C. IR (ATR) \vee 3284 (NH), 1664 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.48 (t, 3H, *J* = 7.1 Hz), 4.43 (dq, 1H, *J* = 10.8, 7.1 Hz), 4.47 (dq, 1H, *J* = 10.8, 7.1 Hz), 5.87 (s, 1H), 7.16 (d, 1H, *J* = 3.1 Hz), 7.59 (d, 1H, *J* = 2.3 Hz), 8.89 (d, 1H, *J* = 2.3 Hz), 9.52 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.5, 82.5, 100.7, 111.6, 113.7,

114.5, 117.6, 119.6, 120.5, 120.9, 129.1, 134.6, 148.0, 160.0. HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₅H₁₁Br₂Cl₃NO₃ 515.8166, found 515.8174.

Ethyl 4-phenyl-4-(trifluoromethyl)-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12da**). Yield 141 mg (73%), mp 100–102 °C. IR (ATR) ν 3366 (NH), 1707 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.42 (t, 3H, *J* = 7.1 Hz), 4.40 (dq, 1H, *J* = 10.8, 7.1 Hz), 4.43 (dq, 1H, *J* = 10.8, 7.1 Hz), 7.00 (ddd, 1H, *J* = 8.0, 7.6, 1.9 Hz), 7.14–7.22 (m, 3H), 7.24–7.31 (m, 3H), 7.48–7.54 (m, 2H), 8.53 (dd, 1H, *J* = 7.9, 1.2 Hz), 9.37 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 85.2 (s, CF₃); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.0, 80.7 (q, *J* = 30.8 Hz), 117.0, 117.5, 117.9, 118.1, 118.7, 121.0, 122.5, 124.1 (q, ¹*J*_{CF} = 283.7 Hz), 127.7, 128.0 (2C), 128.1 (2C), 129.0, 129.2, 135.4, 150.7, 160.2. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₁H₁₇F₃NO₃ 388.1155, found 388.1153.

Ethyl 8-methoxy-4-phenyl-4-(trifluoromethyl)-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12db**). Yield 136 mg (65%), mp 105–107 °C. IR (ATR) ν 3346 (NH), 1714 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.41 (t, 3H, *J* = 7.1 Hz), 3.78 (s, 3H), 4.39 (dq, 1H, *J* = 10.9, 7.1 Hz), 4.42 (dq, 1H, *J* = 10.9, 7.1 Hz), 6.76 (dd, 1H, *J* = 8.8, 3.1 Hz), 7.08 (d, 1H, *J* = 8.8 Hz), 7.16 (dq, 1H, *J* = 2.6, 1.4 Hz), 7.24–7.30 (m, 3H), 7.46–7.52 (m, 2H), 8.21 (d, 1H, *J* = 3.1 Hz), 9.45 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 84.3 (s, CF₃); ¹³C NMR (126 MHz, CDCl₃) δ 14.5, 55.6, 61.0, 80.6 (q, ²*J*_{CF} = 30.8 Hz), 112.1, 115.4, 117.2, 117.5, 117.8, 118.7, 119.2, 121.3, 124.1 (q, ¹*J*_{CF} = 283.6 Hz), 127.9 (2C), 128.2 (2C), 129.0, 135.3, 144.6, 154.8, 160.1. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₂H₁₉F₃NO₄ 418.1261, found 418.1259.

Ethyl 6-ethoxy-4-phenyl-4-(trifluoromethyl)-2,4-dihydrochromeno[3,4-c]pyrrole-1-carboxylate (**12dc**). Yield 136 mg (63%), mp 137–138 °C. IR (ATR) v 3291 (NH), 1668 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.41 (t, 3H, *J* = 7.1 Hz), 1.53 (t, 3H, *J* = 7.0 Hz), 4.13 (dq, 1H, *J* = 9.5, 7.0 Hz), 4.23 (dq, 1H, *J* = 9.5, 7.0 Hz), 4.38 (dq, 1H, *J* = 11.0, 7.1 Hz), 4.42 (dq, 1H, *J* = 11.0, 7.1 Hz), 6.83 (dd, 1H, *J* = 8.0, 1.4 Hz), 6.91 (t, 1H, *J* = 8.0 Hz), 7.21 (dq, 1H, *J* = 2.8, 1.4 Hz), 7.23–7.28 (m, 3H), 7.56–7.63 (m, 2H), 8.10 (dd, 1H, *J* = 8.0, 1.4 Hz), 9.39 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 84.3 (s, CF₃); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 15.0, 60.9, 65.0, 81.2 (q, ²*J*_{CF} = 31.1 Hz), 114.3, 117.5, 117.6, 117.7, 119.8, 120.1, 121.1, 122.2, 124.1 (q, ¹*J*_{CF} = 283.1 Hz), 127.9 (2C), 128.0 (2C), 129.0, 135.0, 140.6, 148.5, 160.2. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₂₃H₂₁F₃NO₄ 432.1417, found 432.1421.

Ethyl 8-chloro-4-phenyl-4-(trifluoromethyl)-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12dd**). Yield 160 mg (76%), mp 158–160 °C. IR (ATR) ν 3457 (NH), 1720 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.47 (t, 3H, *J* = 7.1 Hz), 4.41 (dq, 1H, *J* = 10.9, 7.1 Hz), 4.46 (dq, 1H, *J* = 10.9, 7.1 Hz), 7.05 (d, 1H, *J* = 8.6 Hz), 7.19 (dq, 1H, *J* = 2.6, 1.4 Hz), 7.27–7.31 (m, 4H), 7.43–7.49 (m, 2H), 8.68 (d, 1H, *J* = 2.4 Hz), 9.50 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 84.3. (s, CF₃); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.5, 80.9 (q, ²*J*_{CF} = 31.2 Hz), 115.1, 116.9, 118.0, 118.1, 119.3, 119.8, 120.6, 123.9 (q, ¹*J*_{CF} = 283.6 Hz), 128.1 (4C), 129.3, 130.2, 131.7, 134.9, 149.8, 160.3. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₁H₁₆ClF₃NO₃ 411.0765, found 422.0760.

Ethyl 8-bromo-4-phenyl-4-(trifluoromethyl)-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**12de**). Yield 168 mg (72%), mp 153–155 °C. IR (ATR) v 3283 (NH), 1670 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.47 (t, 3H, *J* = 7.1 Hz), 4.41 (dq, 1H, *J* = 10.9, 7.1 Hz), 4.46 (dq, 1H, *J* = 10.9, 7.1 Hz), 7.05 (d, 1H, *J* = 8.6 Hz), 7.19 (dq, 1H, *J* = 2.8, 1.5 Hz), 7.27–7.31 (m, 4H), 7.43–7.50 (m, 2H), 8.68 (d, 1H, *J* = 2.4 Hz), 9.47 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 84.3 (s, CF₃); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.5, 80.9 (q, ²*J*_{CF} = 31.2 Hz), 115.1, 116.9, 118.0, 118.1, 119.3, 119.8, 120.6, 123.9 (q, *J* = 283.6 Hz), 128.1 (4C), 129.2, 130.2, 131.7, 134.9, 149.8, 160.3. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₂₁H₁₆BrF₃NO₃ 466.0260, found 466.0262.

Ethyl 6,8-*dichloro*-4-*phenyl*-4-(*trifluoromethyl*)-2,4-*dihydrochromeno*[3,4-*c*]*pyrrole*-1-*carboxylate* (**12df**). Yield 155 mg (68%), mp 172–173 °C. IR (ATR) v 3291 (NH), 1687 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.45 (t, 3H, *J* = 7.1 Hz), 4.40 (dq, 1H, *J* = 10.9, 7.1 Hz), 4.46 (dq, 1H, *J* = 10.9, 7.1 Hz), 7.23 (dq, 1H, *J* = 2.8, 1.5 Hz), 7.25 (d, 1H, *J* = 2.5 Hz), 7.28–7.34 (m, 3H), 7.51–7.57 (m, 2H), 8.49 (d, 1H, *J* = 2.5 Hz), 9.50 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 84.3 (s, CF₃); ¹³C NMR (126 MHz, CDCl₃) δ 14.3, 61.5, 82.0 (q, ²*J*_{CF} = 31.6 Hz), 117.1, 117.9, 118.4, 119.0, 121.4, 123.7 (q, ¹*J*_{CF} = 283.6 Hz), 123.8, 126.0, 127.5, 128.0 (2C), 128.2 (2C), 129.0, 129.5, 134.2, 145.3, 159.9. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₂₁H₁₅Cl₂F₃NO₃ 456.0376, found 456.0374.

Ethyl 6,8-dibromo-4-phenyl-4-(trifluoromethyl)-2,4-dihydrochromeno[3,4-*c*]*pyrrole-1-carboxylate* (**10dg**). Yield 191 mg (70%), mp 181–183 °C. IR (ATR) ν 3246 (NH), 1683 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.46 (t, 3H, *J* = 7.1 Hz), 4.41 (dq, 1H, *J* = 10.8, 7.1 Hz), 4.46 (dq, 1H, *J* = 10.8, 7.1 Hz), 7.22 (dq, 1H, *J* = 2.8, 1.5 Hz), 7.28–7.35 (m, 3H), 7.52–7.60 (m, 3H), 8.67 (d, *J* = 2.3 Hz, 1H), 9.52 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 84.3 (s, CF₃); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.5, 82.2 (q, ²*J*_{CF} = 31.7 Hz), 112.8, 115.0, 117.0, 117.9, 118.4, 118.9, 121.8, 123.7 (q, ¹*J*_{CF} = 283.6 Hz), 128.1 (2C), 128.2 (2C), 129.4, 129.5, 134.2, 134.5, 146.8, 160.0. HRMS (ESI) *m*/*z*: [M + H]⁺ calcd for C₂₁H₁₅Br₂F₃NO₃ 543.9365, found 543.9365.

3.3. Synthesis of Compounds 13–15

Ethyl 2-methyl-4-(trifluoromethyl)-2,4-dihydrochromeno[*3,4-c*]*pyrrole-1-carboxylate* (**13**). A mixture of 2,4-dihydrochromeno[*3,4-c*]*pyrrole* **12aa** (156 mg, 0.5 mmol), iodomethane (106 mg, 1.5 mmol) and K₂CO₃ (138 mg, 1.0 mmol) in acetone (3 mL) was heated at 40 °C for 18 h with stirring. Upon completion of the reaction, the mixture was poured into ice water (25 mL) and the precipitate was filtered and washed with water (10 × 5 mL). Yield 124 mg (76%), white powder, mp 68–70 °C. IR (ATR) v 1690 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.43 (t, 3H, *J* = 7.1 Hz), 3.91 (s, 3H), 4.42 (q, 2H, *J* = 7.1 Hz), 5.47 (q, 1H, *J* = 6.7 Hz), 6.76 (s, 1H), 6.99–7.06 (m, 2H), 7.15–7.21 (ddd, 1H, *J* = 8.1, 7.8, 1.4 Hz), 8.28 (dd, 1H, *J* = 7.8, 1.4 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ 83.2 (d, *J* = 6.7 Hz, CF₃); ¹³C NMR (126 MHz, CDCl₃) δ 14.2, 38.5, 60.8, 70.9 (q, ²*J*_{CF} = 34.0 Hz), 110.2, 117.1, 118.6, 118.7, 121.7, 122.2, 123.4 (q, ¹*J*_{CF} = 283.6 Hz), 124.2, 127.0, 128.6, 151.8, 161.4. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₆H₁₅F₃NO₃ 326.0999, found 326.1004.

Ethyl 2-*phenyl*-4-(*trifluoromethyl*)-2,4-*dihydrochromeno*[3,4-*c*]*pyrrole*-1-*carboxylate* (14). A mixture of chromene **10aa** (138 mg, 0,5 mmol), phenylboronic acid (122 mg, 1.0 mmol), Et₃N (139 μL, 101 mg 1.0 mmol) and Cu(OAc)₂ (91 mg, 0.5 mmol) in 1,2-dichloroethane (3 mL) was refluxed with stirring for 20 h. Upon completion of the reaction, the residue was evaporated under reduced pressure to complete dryness. The residue was purified by silica gel column chromatography (eluent EtOAc–hexane (1:3)). Yield 87 mg (45%), white powder, mp 115–116 °C. IR (ATR) v 1682 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 0.92 (t, 3H, *J* = 7.1 Hz), 4.08 (q, 2H, *J* = 7.1 Hz), 5.57 (qd, 1H, *J* = 6.6, 0.5 Hz), 6.92 (s, 1H), 7.03–7.09 (m, 2H), 7.22 (ddd, 1H, *J* = 8.1, 7.5, 1.6 Hz), 7.29–7.34 (m, 2H), 7.39–7.48 (m, 3H), 8.39–8.43 (m, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 83.3 (d, *J* = 6.6 Hz, CF₃); ¹³C NMR (126 MHz, CDCl₃) δ 13.5, 60.7, 70.9 (q, ²*J*_{CF} = 34.1 Hz), 111.2, 117.1, 118.0, 119.6, 122.0, 122.5, 123.4 (q, ¹*J*_{CF} = 283.6 Hz), 123.5, 125.6 (2C), 126.8, 128.0, 129.0 (2C), 129.1, 141.0, 151.7, 161.3. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₁H₁₇F₃NO₃ 388.1155, found 388.1160.

Ethyl 3-bromo-4-(trifluoromethyl)-2,4-dihydrochromeno[3,4-c]pyrrole-1-carboxylate (15). To a solution of pyrrole **3aa** (0.5 mmol) cooled to 0–5 °C in CHCl₃ (5 mL), NBS (98 mg, 0.55 mmol) was added portionwise within 25 min with stirring. Then, the reaction mixture was stirred overnight and the precipitate was filtered and washed with CHCl₃ (1 mL). The solution was evaporated under reduced pressure to complete dryness, washed with water (3 × 5 mL), and recrystallized from 70% ethanol. Yield 107 mg (55%), white powder, mp 165–167 °C. IR (ATR) v 3225 (NH), 1665 (C=O). ¹H NMR (400 MHz, CDCl₃) δ 1.44 (t, 3H, *J* = 7.1 Hz), 4.42 (dq, 1H, *J* = 11.6, 7.1 Hz), 4.45 (dq, 1H, *J* = 11.6, 7.1 Hz), 5.44 (q, 1H, *J* = 6.7 Hz), 7.03–7.09 (m, 2H), 7.24 (td, 1H, *J* = 7.8, 1.5 Hz), 8.62 (dd, 1H, *J* = 7.8, 1.5 Hz), 9.42 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ 83. 8 (d, *J* = 6.7 Hz, CF₃); ¹³C NMR (126 MHz, CDCl₃) δ 14.4, 61.3, 69.8 (q, ²*J*_{CF} = 34.1 Hz), 102.4, 112.1, 117.0, 117.1, 118.5, 122.6 (2C), 123.5 (q, ¹*J*_{CF} = 286.7 Hz), 127.8, 129.8, 151.8, 159.3. HRMS (ESI) *m*/*z*: [M+H]⁺ calcd for C₁₅H₁₂BrF₃NO₃ 389.9947, found 389.9955.

Supplementary Materials: The following supporting information can be downloaded at: https://doi.org/10.3390/molecules27238456, S2–S32: NMR spectra of compounds **12–15**.

Author Contributions: Conceptualization and methodology were provided by A.Y.B. and V.Y.K. A.Y.B., I.A.K. and V.Y.K. conceived and designed the experiments. A.Y.B., I.A.K., N.S.Z. and V.Y.K. analyzed the results. The experimental work was conducted by I.A.K., V.Y.K. and V.Y.S. wrote the

paper. Project administration and funding acquisition were carried out by V.Y.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Russian Foundation for Basic Research (project 20-03-00716) and the Ministry of Science and Higher Education of the Russian Federation (project FEUZ-2020-0052).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within the article and Supplementary Material.

Acknowledgments: Analytical studies were carried out using equipment at the Center for Joint Use 'Spectroscopy and Analysis of Organic Compounds' at the Postovsky Institute of Organic Synthesis of the Russian Academy of Sciences (Ural Branch).

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from the authors.

References

- 1. Fukuda, T.; Ishibashi, F.; Iwao, M. Lamellarin alkaloids: Isolation, synthesis, and biological activity. In *The Alkaloids: Chemistry and Biology*, 1st ed.; Elsevier Inc.: Amsterdam, The Netherlands, 2020; Volume 83, pp. 1–112.
- 2. Seipp, K.; Geske, L.; Opatz, T. Marine Pyrrole Alkaloids. Mar. Drugs 2021, 19, 514. [CrossRef] [PubMed]
- 3. Bailly, C. Anticancer Properties of Lamellarins. Mar. Drugs 2015, 13, 1105–1123. [CrossRef] [PubMed]
- 4. Chittchang, M.; Batsomboon, P.; Ruchirawat, S.; Ploypradith, P. Cytotoxicities and structure–activity relationships of natural and unnatural lamellarins toward cancer cell lines. *ChemMedChem* **2009**, *4*, 457–465. [CrossRef] [PubMed]
- 5. Quesada, A.R.; Grávalos, M.D.G.; Fernandez Puentes, J.L. Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein. *Cancer* **1996**, *74*, 677–682. [CrossRef] [PubMed]
- 6. Ridley, C.P.; Reddy, M.V.R.; Rocha, G.; Bushman, F.D.; Faulkner, D.J. Total synthesis and evaluation of lamellarin α 20-sulfate analogues. *Bioorg. Med. Chem.* 2002, *10*, 3285–3290. [CrossRef]
- Baral, N.; Mishra, D.R.; Mishra, N.P.; Mohapatra, S.; Raiguru, B.P.; Panda, P.; Nayak, S.; Nayak, M.; Kumar, P.S. Microwaveassisted rapid and efficient synthesis of chromene-fused pyrrole derivatives through multicomponent reaction and evaluation of antibacterial activity with molecular docking investigation. J. Heterocycl. Chem. 2020, 57, 575–589. [CrossRef]
- 8. Thakur, A.; Thakur, M.; Khadikar, P. Topological modeling of benzodiazepine receptor binding. *Bioorg. Med. Chem.* 2003, 11, 5203–5207. [CrossRef]
- 9. Faty, R.A.M.; Mourad, A.K.; Abd Elmotaleb, R.M.; Radewan, R.M. Synthesis, antibacterial activity, and fluorescence properties of a novel series from [2,4-dioxochromen-3(4H)methyl]amino acid. *Res. Chem. Intermed.* **2018**, *44*, 1551–1567. [CrossRef]
- 10. Shen, Y.-M.; Grampp, G.; Leesakul, N.; Hu, H.-W.; Xu, J.-H. Synthesis and emitting properties of the blue-light fluorophores indolizino[3,4,5-*ab*]isoindole derivatives. *Eur. J. Org. Chem.* **2007**, 2007, 3718–3726. [CrossRef]
- El-Sawy, E.R.; Abdelwahab, A.B.; Kirsch, G. Synthetic Routes to Coumarin(Benzopyrone)-Fused Five-Membered Aromatic Heterocycles Built on the α-Pyrone Moiety. Part 1: Five-Membered Aromatic Rings with One Heteroatom. *Molecules* 2021, 26, 483. [CrossRef]
- 12. Cui, H.-L. Recent progress in the synthesis of pyrrolo[2,1-a]isoquinolines. Org. Biomol. Chem. 2022, 20, 2779–2801. [CrossRef]
- 13. Samanta, K.; Patra, P.; Kar, G.K.; Dinda, S.K.; Mahanty, D.S. Diverse synthesis of pyrrolo/indolo[3,2-c]coumarins as isolamellarin-A scaffolds: A brief update. *New J. Chem.* **2021**, *45*, 7450–7485. [CrossRef]
- 14. Sarkar, S.; Samanta, R. Weakly coordinating *tert*-amide-assisted Ru(II)-catalyzed synthesis of azacoumestans via migratory insertion of quinoid carbene: Application in the total synthesis of isolamellarins. *Org. Lett.* **2022**, *24*, 4536–4541. [CrossRef]
- 15. Patra, P. A short review on the synthesis of pyrrolo[3,4-*c*]coumarins an isolamellarin-B scaffolds. *Synth. Commun.* **2022**, *52*, 1999–2018. [CrossRef]
- Xue, S.; Yao, J.; Liu, J.; Wang, L.; Liu, X.; Wang, C. Three-component reaction between substituted 2-(2-nitrovinyl)phenols, acetylenedicarboxylate and amines: Diversity-oriented synthesis of novel pyrrolo[3,4-c]coumarins. *RSC Adv.* 2016, 6, 1700–1704. [CrossRef]
- Shaabani, A.; Sepahvand, H.; Bazgir, A.; Khavasi, H.R. Tosylmethylisocyanide (TosMIC) [3+2] cycloaddition reactions: A facile Van Leusen protocol for the synthesis of the new class of spirooxazolines, spiropyrrolines and chromeno[3,4-*c*]pyrrols. *Tetrahedron* 2018, 74, 7058–7067. [CrossRef]
- 18. Alizadeh, A.; Ghanbaripour, R.; Zhu, L.-G. An approach to the synthesis of 2-acylchromeno[3,4-*c*]pyrrol-4(2*H*)-one derivatives via a sequential three-component reaction. *Synlett* **2013**, *24*, 2124–2126. [CrossRef]
- Mondal, S.K.; Mandal, A.; Manna, S.K.; Ali, S.A.; Hossain, M.; Venugopal, V.; Jana, A.; Samanta, S. Intramolecular macrolactonization, photophysical and biological studies of new class of polycyclic pyrrole derivatives. *Org. Biomol. Chem.* 2017, *15*, 2411–2421. [CrossRef]

- Jana, A.; Manna, S.K.; Mondal, S.K.; Mandal, A.; Manna, S.K.; Jana, A.; Senapati, B.K.; Jana, M.; Samanta, S. An efficient synthesis of pyrrole and fluorescent isoquinoline derivatives using NaN₃/NH₄Cl promoted intramolecular aza-annulation. *Tetrahedron Lett.* 2016, 57, 3722–3726. [CrossRef]
- Wang, L.; Zhang, Y.; Miao, A.-Q.; Zhang, T.-S.; Wang, X.; Hao, W.-J.; Tu, S.-J.; Jiang, B. Nitrative bicyclization of 1,7-diynes for accessing skeletally diverse tricyclic pyrroles. *Chem. Commun.* 2022, 58, 4376–4379. [CrossRef]
- Grigg, R.; Vipond, D. 4-Phenylsulphinyl- and 4-phenylsulphonylcoumarins as 2π-components in cycloaddition reactions. *Tetrahedron* 1989, 45, 7587–7592. [CrossRef]
- 23. Shekarrao, K.; Kaishap, P.P.; Gogoi, S.; Boruaha, R.C. Palladium-catalyzed one-pot Sonogashira coupling, *exo-dig* cyclization and hydride transfer reaction: Synthesis of pyridine-substituted pyrroles. *Adv. Synth. Catal.* **2015**, 357, 1187–1192. [CrossRef]
- 24. Campeau, D.; Pommainville, A.; Gagosz, F. Ynamides as three-atom components in cycloadditions: An unexplored chemical reaction space. *J. Am. Chem. Soc.* 2021, 143, 9601–9611. [CrossRef] [PubMed]
- 25. Gabbutt, C.D.; Hepworth, J.D.; Heron, B.M.; Pugh, S.L. A facile route to pyrroles, isoindoles and hetero fused analogues. *J. Chem. Soc. Perkin Trans.* 1 2002, 2799–2808. [CrossRef]
- Hong, F.-L.; Shi, C.-Y.; Hong, P.; Zhai, T.-Y.; Zhu, X.-Q.; Lu, X.; Ye, L.-W. Copper-catalyzed asymmetric diyne cyclization via [1,2]-Stevens-type rearrangement for the synthesis of chiral chromeno[3,4-c]pyrroles. *Angew. Chem. Int. Ed.* 2022, *61*, e202115554. [CrossRef]
- 27. Barton, D.H.R.; Zard, S.Z. A new synthesis of pyrroles from nitroalkenes. J. Chem. Soc. Chem. Commun. 1985, 1098–1100. [CrossRef]
- Barton, D.H.R.; Kervagoret, J.; Zard, S.Z. A useful synthesis of pyrroles from nitroolefins. *Tetrahedron* 1990, 46, 7587–7598. [CrossRef]
- 29. Ono, N.; Okujima, T. Synthesis of pyrroles and their derivatives from isocyanides. In *Isocyanide Chemistry. Applications in Synthesis and Material Science*, 1st ed.; Nenajdenko, V.G., Ed.; Wiley-VCH: Weinheim, Germany, 2012; pp. 385–429.
- Motornov, V.A.; Ioffe, S.L.; Tabolin, A.A. [3+2]-Annulation reactions with nitroalkenes in the synthesis of aromatic five-membered nitrogen heterocycles. In *Targets Heterocyclic Systems*; Attanasi, O.A., Spinelli, D., Eds.; Royal Society of Chemistry: Cambridge, UK, 2019; Volume 23, pp. 237–260.
- Silyanova, E.A.; Samet, A.V.; Salamandra, L.K.; Khrustalev, V.N.; Semenov, V.V. Formation of 3,4-diarylpyrrole- and pyrrolocoumarin core of natural marine products via Barton-Zard reaction and selective O-demethylation. *Eur. J. Org. Chem.* 2020, 2020, 2093–2100. [CrossRef]
- 32. Das, S. 3-Nitrochromenes in the synthesis of fused- and spiro scaffolds: Recent progress. *Synth. Commun.* **2022**, *52*, 637–666. [CrossRef]
- Korotaev, V.Y.; Kutyashev, I.B.; Barkov, A.Y.; Sosnovskikh, V.Y. Recent advances in the chemistry of 3-nitro-2H- and 3-nitro-4Hchromenes. Russ. Chem. Rev. 2019, 88, 27–58. [CrossRef]
- 34. Korotaev, V.Y.; Sosnovskikh, V.Y.; Barkov, A.Y. Synthesis and properties of 3-nitro-2*H*-chromenes. *Russ. Chem. Rev.* 2013, *82*, 1081–1116. [CrossRef]
- 35. Purser, S.; Moore, P.R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry. Chem. Soc. Rev. 2008, 37, 320–330. [CrossRef]
- Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J.L.; Soloshonok, V.A.; Izawa, K.; Liu, H. Next generation of fluorinecontaining pharmaceuticals, compounds currently in phase II–III clinical trials of major pharmaceutical companies: New structural trends and therapeutic areas. *Chem. Rev.* 2016, *116*, 422–518. [CrossRef]
- Kutyashev, I.B.; Ulitko, M.V.; Barkov, A.Y.; Zimnitskiy, N.S.; Korotaev, V.Y.; Sosnovskikh, V.Y. A regio- and stereocontrolled approach to the synthesis of 4-CF₃-substituted spiro[chromeno[3,4-c]pyrrolidine-oxindoles] via reversible [3+2] cycloaddition of azomethine ylides generated from isatins and sarcosine to 3-nitro-2-(trifluoromethyl)-2H-chromenes. *New J. Chem.* 2019, 43, 18495–18504.
- Kutyashev, I.B.; Ulitko, M.V.; Barkov, A.Y.; Zimnitskiy, N.S.; Korotaev, V.Y.; Sosnovskikh, V.Y. Regio- and stereoselective 1,3-dipolar cycloaddition of azomethine ylides based on isatins and (thia)proline to 3-nitro-2-(trifluoro(trichloro)methyl)-2H-chromenes: Synthesis and cytotoxic activity of 6-(trihalomethyl)spiro[chromeno(thia)pyrrolizidine-11,3'-indolin]-2'-ones. *Chem. Heterocycl. Compd.* 2021, 57, 751–763.
- Barkovskii, S.V.; Ulitko, M.V.; Kochnev, I.A.; Zimnitskiy, N.S.; Korotaev, V.Y.; Sosnovskikh, V.Y.; Stepanyuk, R.A.; Madzhidov, T.I. The synthesis and cytotoxic activity of *N*-unsubstituted 3-aryl-4-(trifluoromethyl)-4H-spiro[chromeno[3,4-c]pyrrolidine-1,11'indeno[1,2-b]quinoxalines]. *Chem. Heterocycl. Compd.* 2022, 58, 462–472. [CrossRef]
- Korotaev, V.Y.; Kutyashev, I.B.; Barkov, A.Y.; Sosnovskikh, V.Y. 3-Nitro-2-(trihalomethyl)-2*H*-chromenes in reactions with sodium azide: Synthesis of 4-(trihalomethyl)-2,4-dihydrochromeno[3,4-d][1,2,3]triazoles. *Chem. Heterocycl. Compd.* 2017, 53, 597–603. [CrossRef]
- Korotaev, V.Y.; Kutyashev, I.B.; Sosnovskikh, V.Y. Synthesis of 3-substituted 2-trifluoro(trichloro)methyl-2H-chromenes by reaction of salicylaldehydes with activated trihalomethyl alkenes. *Heteroat. Chem.* 2005, 16, 492–496. [CrossRef]
- Sakakibara, T.; Koezuka, M.; Sudoh, R. A convenient synthesis of 2-substituted 3-nitro-2H-chromene derivatives. Bull. Chem. Soc. Jpn. 1978, 51, 3095–3096. [CrossRef]
- Barkov, A.Y.; Korotaev, V.Y.; Kotovich, I.V.; Zimnitskiy, N.S.; Kutyashev, I.B.; Sosnovskikh, V.Y. 3-Nitro-2-phenyl-2-(trifluoromethyl)-2H-chromenes: Synthesis and reactions with nucleophiles. *Chem. Heterocycl. Compd.* 2016, 52, 814–822. [CrossRef]

- 45. Lam, P.Y.S.; Clark, C.G.; Saubern, S.; Adams, J.; Winters, M.P.; Chan, D.M.T.; Combs, A. New aryl/heteroaryl C-N bond cross-coupling reactions via arylboronic acid/cupric acetate arylation. *Tetrahedron Lett.* **1998**, *39*, 2941–2944. [CrossRef]
- 46. Kawamata, Y.; Ito, S.; Furuya, M.; Takahashi, K.; Namai, K.; Hashimoto, S.; Roppongi, M.; Oba, T. Synthesis and properties of novel extended BODIPYs with rigid skeletons. *Tetrahedron Lett.* **2019**, *60*, 707–712. [CrossRef]